Guggenheim analyst Chris Pasquale expects FDA approval of Spectranetics' Stellarex device for peripheral arterial disease to spark significant growth acceleration by the company. After speaking with 25 "high-volume interventional cardiologists" about Stellarex's outlook, Pasquale says that the checks are "highly encouraging." Specifically, the analyst reports that the doctors see the drug as "a best-in-class product," and he thinks that investors could be "significantly underestimating" the outlook for the drug's market share. He keeps a $35 price target and a Buy rating on the name.